Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03609827 · ClinicalTrials.gov registry record
Study of Melphalan Drug Exposure in Pediatric Hematopoietic Stem Cell Transplant Patients
A clinical trial of Sickle Cell Disease and Hematologic Malignancies, sponsored by University of California, San Francisco.
- Completed
- Registry status
- 25
- Enrollment target
- 1
- Study location
NCT03609827 is a study of Sickle Cell Disease and Hematologic Malignancies that has completed, run by University of California, San Francisco. The registered enrollment target is 25 participants, below the 293-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03609827, a study of Sickle Cell Disease and Hematologic Malignancies, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
Melphalan is a chemotherapy drug used extensively in bone marrow transplantation. The goal of this study is to determine what causes some children to have different drug concentrations of melphalan in their bodies and if drug levels are related to whether or not a child experiences severe side-effects during their bone marrow transplant. The hypothesis is that certain clinical and individual factors cause changes in melphalan drug levels in pediatric bone marrow transplant patients and that high levels may cause severe side-effects.
Conditions Studied
Interventions
- DRUG Melphalan
Study Locations (1)
California
- University of California, San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2015-09-01 |
| Est. Completion | 2021-05-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03609827
The ClinicalTrials.gov registry entry for NCT03609827 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 293-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (91% lower). The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 8 conditions, with Sickle Cell Disease appearing as the primary indexed condition, and to 1 intervention - of which Melphalan is the first listed.
NCT03609827 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT03609827 about?
NCT03609827 is a clinical study titled "Study of Melphalan Drug Exposure in Pediatric Hematopoietic Stem Cell Transplant Patients". Melphalan is a chemotherapy drug used extensively in bone marrow transplantation. The goal of this study is to determine what causes some children to have different drug concentrations of melphalan in their bodies and if drug levels are related to whether or not a child experiences severe side-effec...
What is the current status of trial NCT03609827?
This trial is currently completed. The enrollment target is 25 participants. The study started on 2015-09-01. Estimated completion is 2021-05-31.
What conditions does trial NCT03609827 study?
This clinical trial studies the following conditions: Sickle Cell Disease, Hematologic Malignancies, Thalassemia, Hemoglobinopathies, Immunodeficiencies.
What interventions are being tested in trial NCT03609827?
The interventions under investigation include: Melphalan (DRUG).
Who is sponsoring clinical trial NCT03609827?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03609827 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sickle Cell Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults
RECRUITING · Phase 2
-
Early Life Exposures Among Children With Sickle Cell Disease
RECRUITING · NA
-
Exercise in Child Health
RECRUITING · NA
-
Sickle Cell Children's Exercise Study (SuCCESs)
RECRUITING · NA
-
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
RECRUITING · Phase 1
-
Hematopoietic Stem Cell BCL11A Enhancer Gene Editing for Severe β-Hemoglobinopathies
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.